Analysis of structure-based virtual screening studies and characterization of identified active compounds.
暂无分享,去创建一个
Jürgen Bajorath | Dagmar Stumpfe | Peter Ripphausen | J. Bajorath | Dagmar Stumpfe | Peter Ripphausen
[1] Jana Sopkova-de Oliveira Santos,et al. Virtual Screening Discovery of New Acetylcholinesterase Inhibitors Issued from CERMN Chemical Library , 2010, J. Chem. Inf. Model..
[2] Volodymyr G Bdzhola,et al. Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. , 2006, Journal of medicinal chemistry.
[3] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[4] Xin Chen,et al. Discovery of Novel Pim-1 Kinase Inhibitors by a Hierarchical Multistage Virtual Screening Approach Based on SVM Model, Pharmacophore, and Molecular Docking , 2011, J. Chem. Inf. Model..
[5] C. Bock,et al. Discovery of novel types of inhibitors of S-adenosylmethionine synthesis by virtual screening. , 2009, Journal of medicinal chemistry.
[6] A. Pierce,et al. Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase. , 2008, Journal of medicinal chemistry.
[7] J. Bajorath,et al. Quo vadis, virtual screening? A comprehensive survey of prospective applications. , 2010, Journal of medicinal chemistry.
[8] Megan L. Peach,et al. Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening. , 2009, Journal of medicinal chemistry.
[9] W. Geldenhuys,et al. Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening. , 2010, Bioorganic & medicinal chemistry letters.
[10] Robert P. Sheridan,et al. Comparison of Topological, Shape, and Docking Methods in Virtual Screening. , 2007 .
[11] György M. Keserü. Structure-Based Virtual Screening , 2007 .
[12] M. Mizutani,et al. Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors. , 2004, Journal of medicinal chemistry.
[13] Angela Rao,et al. Structure‐Based Pharmacophore Identification of New Chemical Scaffolds as Non‐Nucleoside Reverse Transcriptase Inhibitors. , 2007 .
[14] Kyungik Lee,et al. Structure-based virtual screening of Src kinase inhibitors. , 2009, Bioorganic & medicinal chemistry.
[15] Jürgen Bajorath,et al. Virtual compound screening in drug discovery. , 2012, Future medicinal chemistry.
[16] David S. Wishart,et al. Development of a Novel Virtual Screening Cascade Protocol to Identify Potential Trypanothione Reductase Inhibitors , 2009, Journal of medicinal chemistry.
[17] J. Bajorath,et al. State-of-the-art in ligand-based virtual screening. , 2011, Drug discovery today.
[18] Victor A Kenyon,et al. Novel human lipoxygenase inhibitors discovered using virtual screening with homology models. , 2006, Journal of medicinal chemistry.
[19] Thierry Langer,et al. Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. , 2008, Journal of medicinal chemistry.
[20] Scott A. Busby,et al. A Combined Ligand‐ and Structure‐Based Virtual Screening Protocol Identifies Submicromolar PPARγ Partial Agonists , 2011, ChemMedChem.
[21] B. Shoichet,et al. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. , 2002, Journal of medicinal chemistry.
[22] Gisbert Schneider,et al. Virtual screening and fast automated docking methods. , 2002, Drug discovery today.
[23] Claudio N. Cavasotto,et al. Homology modeling in drug discovery: current trends and applications. , 2009, Drug discovery today.
[24] Alexander D. MacKerell,et al. Identification and validation of human DNA ligase inhibitors using computer-aided drug design. , 2008, Journal of medicinal chemistry.
[25] Alexander D. MacKerell,et al. Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction. , 2004, Journal of medicinal chemistry.
[26] Ying Leng,et al. Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling. , 2008, Bioorganic & medicinal chemistry letters.
[27] O. El-Kabbani,et al. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening. , 2010, European journal of medicinal chemistry.
[28] A. Leach,et al. Prediction of Protein—Ligand Interactions. Docking and Scoring: Successes and Gaps , 2006 .
[29] Richard A Bryce,et al. In silico identification and biochemical characterization of novel inhibitors of NQO1. , 2006, Bioorganic & medicinal chemistry letters.
[30] Brian K. Shoichet,et al. Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.
[31] Waseem Ahmed,et al. Identification of acridinyl hydrazides as potent aspartic protease inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[32] R. Brinton,et al. Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases. , 2005, Journal of medicinal chemistry.
[33] Steve Price,et al. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. , 2007, Bioorganic & medicinal chemistry letters.
[34] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[35] Alon Herschhorn,et al. Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1. , 2008, Journal of medicinal chemistry.
[36] C. Abad-Zapatero,et al. Ligand efficiency indices for effective drug discovery , 2007, Expert opinion on drug discovery.
[37] W. Sippl,et al. Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors. , 2011, Bioorganic & medicinal chemistry.
[38] X. Barril,et al. Structure-based discovery of a new class of Hsp90 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[39] George W. A. Milne,et al. Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching. , 1996, Journal of medicinal chemistry.
[40] Ruben Abagyan,et al. Structure-Based Discovery of Novel Chemotypes for Adenosine A 2 A Receptor Antagonists , 2010 .
[41] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[42] Hanna Geppert,et al. Current Trends in Ligand-Based Virtual Screening: Molecular Representations, Data Mining Methods, New Application Areas, and Performance Evaluation , 2010, J. Chem. Inf. Model..
[43] Weihua Li,et al. Discovery of potent ligands for estrogen receptor beta by structure-based virtual screening. , 2010, Journal of medicinal chemistry.
[44] Kaixian Chen,et al. Identification and synthesis of N'-(2-oxoindolin-3-ylidene)hydrazide derivatives against c-Met kinase. , 2011, Bioorganic & medicinal chemistry letters.
[45] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[46] Ying Leng,et al. Structure-based virtual screening for identification of novel 11beta-HSD1 inhibitors. , 2009, European journal of medicinal chemistry.
[47] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[48] Dennis M. Krüger,et al. Comparison of Structure‐ and Ligand‐Based Virtual Screening Protocols Considering Hit List Complementarity and Enrichment Factors , 2010, ChemMedChem.
[49] Vladimir Sobolev,et al. Target specific virtual screening: optimization of an estrogen receptor screening platform. , 2007, Journal of medicinal chemistry.
[50] M. Drysdale,et al. Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping. , 2007, Bioorganic & medicinal chemistry letters.
[51] M. Khanfar,et al. Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening. , 2010, Journal of medicinal chemistry.
[52] Paul D Lyne,et al. Structure-based virtual screening: an overview. , 2002, Drug discovery today.
[53] Brian K Shoichet,et al. Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. , 2006, Journal of medicinal chemistry.
[54] Roy J. Vaz,et al. Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures. , 2010, Bioorganic & medicinal chemistry letters.
[55] J. T. Metz,et al. Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.
[56] Zhili Zuo,et al. Identification of a sub-micromolar, non-peptide inhibitor of β-secretase with low neural cytotoxicity through in silico screening. , 2010, Bioorganic & medicinal chemistry letters.
[57] Paolo Bonvini,et al. Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. , 2006, Journal of medicinal chemistry.
[58] Gerhard Klebe,et al. Virtual screening for submicromolar leads of tRNA-guanine transglycosylase based on a new unexpected binding mode detected by crystal structure analysis. , 2003, Journal of medicinal chemistry.
[59] Ruben Abagyan,et al. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.
[60] J. Irwin,et al. ZINC ? A Free Database of Commercially Available Compounds for Virtual Screening. , 2005 .
[61] Markus H J Seifert,et al. Targeted scoring functions for virtual screening. , 2009, Drug discovery today.
[62] Maria A Miteva,et al. Structure-based virtual ligand screening: recent success stories. , 2009, Combinatorial chemistry & high throughput screening.
[63] Artem Cherkasov,et al. An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin. , 2008, Journal of medicinal chemistry.
[64] Kazuo Kuwata,et al. Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10. , 2010, Bioorganic & medicinal chemistry.
[65] Giulio Rastelli,et al. Structure-based design of potent aromatase inhibitors by high-throughput docking. , 2011, Journal of medicinal chemistry.